Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancersPelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancersPoster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual MeetingConference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlookSAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics ...